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Effect of porcine circovirus type 2a or 2b on infection kinetics and
pathogenicity of two genetically divergent strains of porcine reproductive
and respiratory syndrome virus in the conventional pig model
Abstract
To determine differences in infection kinetics of two temporally and genetically different type 2 porcine
reproductive and respiratory syndrome virus (PRRSV) isolates in vivo with and without concurrent porcine
circovirus (PCV) type 2a or 2b infection, 62 pigs were randomly assigned to one of seven groups: negative
controls (n = 8); pigs coinfected with a 1992 PRRSV strain (VR-2385) and PCV2a (CoI-92-2a; n = 9), pigs
coinfected with VR-2385 and PCV2b (CoI-92-2b; n = 9), pigs coinfected with a 2006 PRRSV strain
(NC16845b) and PCV2a (CoI-06-2a; n = 9), pigs coinfected with NC16845b and PCV2b (CoI-06-2b; n =
9), pigs infected with VR-2385 (n = 9), and pigs infected with NC16845b (n = 9). Blood samples were
collected before inoculation and at day post-inoculation (dpi) 3, 6, 9 and 12 and tested for the presence of
PRRSV antibody and RNA, PCV2 antibody and DNA, complete blood counts, and interferon gamma (IFN-
γ) levels. Regardless of concurrent PCV2 infection, VR-2385 initially replicated at higher levels and reached
peak replication levels at dpi 6. Pigs infected with VR-2385 had significantly higher amounts of viral RNA in
serum on both dpi 3 and dpi 6, compared to pigs infected with NC16845b. The peak of NC16845b virus
replication occurred between dpi 9 and dpi 12 and was associated with a delayed anti-PRRSV antibody
response in these pigs. PCV2 coinfection resulted in significantly more severe macroscopic and microscopic
lung lesions and a stronger anti-PRRSV IgG response compared to pigs infected with PRRSV alone. This
work further emphasizes in vivo replication differences among PRRSV strains and the importance of
coinfecting pathogens.
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1. Introduction
Porcine reproductive and respiratory syndrome virus
(PRRSV), a single-stranded, positive-sense RNA virus, is
characterized by a high mutation rate with the potential of
genetically diverse strains evolving over time (Forsberg
et al., 2001; Hanada et al., 2005; Pirzadeh et al., 1998;
Rowland et al., 1999). In the past, PRRSV isolates have
emerged within the swine population with varying
degrees of virulence (Fang et al., 2007; Han et al., 2006;
Nelsen et al., 1999) possibly due to a high degree of
mutation and recombination (Yuan et al., 1999, 2000,
2001, 2004). More recently, attention has focused on the
occurrence of high mortality in Chinese swine herds which
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A B S T R A C T
To determine differences in infection kinetics of two temporally and genetically different
type 2 porcine reproductive and respiratory syndrome virus (PRRSV) isolates in vivo with and
without concurrent porcine circovirus (PCV) type 2a or 2b infection, 62 pigs were randomly
assigned to one of seven groups: negative controls (n = 8); pigs coinfected with a 1992 PRRSV
strain (VR-2385) and PCV2a (CoI-92-2a; n = 9), pigs coinfected with VR-2385 and PCV2b
(CoI-92-2b; n = 9), pigs coinfected with a 2006 PRRSV strain (NC16845b) and PCV2a (CoI-06-
2a; n = 9), pigs coinfected with NC16845b and PCV2b (CoI-06-2b; n = 9), pigs infected with
VR-2385 (n = 9), and pigs infected with NC16845b (n = 9). Blood samples were collected
before inoculation and at day post-inoculation (dpi) 3, 6, 9 and 12 and tested for the presence
of PRRSV antibody and RNA, PCV2 antibody and DNA, complete blood counts, and interferon
gamma (IFN-g) levels. Regardless of concurrent PCV2 infection, VR-2385 initially replicated
at higher levels and reached peak replication levels at dpi 6. Pigs infected with VR-2385 had
signiﬁcantly higher amounts of viral RNA in serum on both dpi 3 and dpi 6, compared to pigs
infected with NC16845b. The peak of NC16845b virus replication occurred between dpi 9
and dpi 12 and was associated with a delayed anti-PRRSV antibody response in these pigs.
PCV2 coinfection resulted in signiﬁcantly more severe macroscopic and microscopic lung
lesions and a stronger anti-PRRSV IgG response compared to pigs infected with PRRSV alone.
This work further emphasizes in vivo replication differences among PRRSV strains and the
importance of coinfecting pathogens.
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was associated with novel PRRSV isolates and described as
porcine high fever disease in 2006 (Tian et al., 2007; Tong
et al., 2007; Wu et al., 2009). The PRRSV isolates involved in
porcine high fever disease contained unique nucleotide
differences compared to other isolates. Speciﬁcally, a
discontinuous, 30 amino acid deletion was identiﬁed
within the nsp2 region which was initially suggested to be
correlated with the pathogenicity of the virus (Tian et al.,
2007; Wu et al., 2009). However, more recent reports have
concluded that this deletion is unrelated to virulence (Zhou
et al., 2009) in spite of the high mortality that was initially
associated with this PRRSV variant (Tian et al., 2007; Tong
et al., 2007). Interestingly, analysis of 582 samples from
affected pigs resulted in the identiﬁcation of PRRSV,
porcine circovirus type 2 (PCV2) and classical swine fever
virus as the most common co-infection pathogens,
suggesting that a potential synergistic interaction among
these viruses may account for the unusually high mortality
(Lv et al., 2008; Wu et al., 2009).
PCV2 is a small, circular, non-enveloped DNA virus
belonging to the Circoviridae family in the genus Circovirus.
PCV2 can be further divided into several subtypes of which
PCV2a and PCV2b are prevalent worldwide (Patterson and
Opriessnig, 2010). To date, experimental infections com-
paring PCV2a and PCV2b in gnotobiotic and conventional
pigs have not demonstrated major differences in virulence
(Beach et al., 2010; Fort et al., 2008; Lager et al., 2007;
Opriessnig et al., 2008b). PCV2 is the cause of porcine
circovirus associated disease (PCVAD) with multiple
clinical manifestations including respiratory disease
(Harms et al., 2002). PRRSV has become an important
component of the porcine respiratory disease complex
(PRDC) with major economic impact on the swine industry
(Chae, 2005). Retrospective studies identiﬁed PRRSV as the
most common cofactor in cases of PCVAD (Pallare´s et al.,
2002). Experimental coinfection with PRRSV and PCV2 has
yielded mixed results. One study completed in 2002
reported minimal clinical disease or death loss in conven-
tional pigs coinfected with PCV2 and PRRSV (Rovira et al.,
2002). In contrast, in another study, severe clinical disease
and death in 10 of 11 pigs between 10 and 21 days post-
infection (dpi) was reported in dually infected, caesarian-
derived and colostrum-deprived (CDCD) pigs (Harms et al.,
2001). Despite differences in severity of clinical presenta-
tion, experimental coinfection of pigs with PCV2 and
PRRSV has consistently resulted in up-regulation of PCV2
replication (enhanced viremia and PCV2 tissue load) and
increased severity of PRRSV-induced lesions in lung tissues
(Allan et al., 2000; Harms et al., 2001; Rovira et al., 2002).
In North America, both PRRSV and PCV2b have been
identiﬁed in PCVAD outbreaks characterized by excessive
mortality suggesting a synergistic relationship between
these two viruses (Cheung et al., 2007; Gagnon et al., 2007;
Horlen et al., 2007). The objective of this study was to
characterize the infection dynamics and pathogenicity of
two different type 2 PRRSV isolates in a conventional pig
model under the inﬂuence of concurrent PCV2a or PCV2b
infection. The severity of clinical disease, macroscopic and
microscopic lesions, amount of PRRSV and PCV2 antibodies
and nucleic acids in sera, amount of PRRSV and PCV2
antigen associated with lesions, and interferon gamma
(IFN-g) concentrations in serum were measured and
compared between groups.
2. Materials and methods
2.1. Animals, housing, and experimental design
Fifty-three colostrum-fed, crossbred pigs were derived
from sows known to be free of PCV2, PRRSV and
Mycoplasma hyopneumoniae in two separate batches, 44
pigs in batch 1 (B1) and 9 pigs in batch 2 (B2). In addition,
batch 3 (B3) consisted of 9 colostrum-fed crossbred pigs
derived from sows free of PRRSV and M. hyopneumoniae
but seropositive for PCV2. B2 and B3 pigs were challenged
at the same age as B1 pigs but the experiment was
conducted approximately 24 months after B1 pigs. Insufﬁ-
cient numbers of pigs were available from the source herd
for singularly PRRSV-infected groups to be included with
the original experiment. The experimental design and
group designations are summarized in Table 1. All pigs
were housed under the same conditions and treated in a
similar way. All pigs were weaned at three weeks of age
and transported to the Livestock Infectious Disease
Isolation Facility at Iowa State University, Ames, Iowa.
On the day of arrival, all B1 pigs were comingled and
randomly assigned to one of ﬁve rooms each containing 8
or 9 pigs: negative controls (n = 8); pigs coinfected with a
1992 isolate of PRRSV (VR-2385) and PCV2a (CoI-92-2a;
n = 9), pigs coinfected with PRRSV VR-2385 and PCV2b
(CoI-92-2b; n = 9), pigs coinfected with a 2006 isolate of
PRRSV (NC16845b) and PCV2a (CoI-06-2a; n = 9) and pigs
Table 1
Experimental design and group designations.
Group designation Batcha Number of pigs PCV2 inoculum PRRSV inoculum
Negative controls 1 8 None None
CoI-92-2a 1 9 PCV2a VR-2385
CoI-92-2b 1 9 PCV2b VR-2385
CoI-06-2a 1 9 PCV2a NC16845b
CoI-06-2b 1 9 PCV2b NC16845b
PRRSV-I-92 2 4 None VR-2385
PRRSV-I-06 2 5 None NC16845b
B3-PRRSV-I-92 3 5 None VR-2385
B3-PRRSV-I-06 3 4 None NC16845b
a Batch 1 and 2 pigs were derived from the same source herd free of PRRSV and PCV2 whereas batch 3 pigs were derived from a different source herd
seropositive for PCV2.
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coinfected with PRRSV NC16845b and PCV2b (CoI-06-2b;
n = 9). B2 pigs were randomly assigned to one of two rooms
each containing 4 or 5 pigs which were infected with
PRRSV VR-2385 (PRRSV-I-92) and PRRSV NC16845b
(PRRSV-I-06), respectively. Similarly, B3 pigs were
comingled and randomly assigned to one of two rooms
each containing 4 or 5 pigs that were infected with PRRSV
VR-2385 (B3-PRRSV-I-92) and PRRSV NC16845b (B3-
PRRSV-I-06), respectively.
The pigs from the different batches were kept in
different but identical rooms. Each room had 18 m2 of solid
concrete ﬂoor space, separate ventilation systems and one
nipple drinker. Inoculation was conducted at approxi-
mately 23 days of age. Blood samples were collected from
all pigs prior to inoculation and at dpi 3, 6, 9 and 12 in
serum separator tubes (8.5 ml BD Vacutainer, Benton
Dixon, Franklin Lakes, NJ, USA). The blood was centrifuged
at 2000  g for 10 min at 4 8C and serum was stored at
80 8C until testing. Serum samples were analyzed for
levels of anti-PCV2 IgG antibody, anti-PRRSV-IgG antibody,
IFN-g, PCV2 DNA, and PRRSV RNA. In addition, EDTA tubes
(8.5 mL MONOJECTTM 15% EDTA liquid, Tyco Healthcare
Group LP, Mansﬁeld, MA, USA) were collected at dpi 3, 6, 9,
and 12, stored at room temperature and used within 12 h
after collection to determine blood cell counts. All pigs
were necropsied on dpi 12 and tissues collected during
necropsy were analyzed by immunohistochemistry (IHC)
for the presence of PCV2 and PRRSV antigens. The
experimental protocol was approved by Iowa State
University Institutional Animal Care and Use Committee
(IACUC approval # 7-08-6595-S).
2.2. Inocula and inoculation
2.2.1. PRRSV
PRRSV isolate VR-2385 with a RFLP pattern 1-3-4 was
recovered in 1992 from pig tissues obtained from a 160 sow
herd in southwestern Iowa affected by severe respiratory
disease in 3–16-week-old pigs and high numbers of late
term abortions (Halbur et al., 1995b; Meng et al., 1994). The
passage 5 virus of the original VR-2385 isolate was used to
inoculate pigs in 2001 as described previously (Opriessnig
et al., 2002). Serum from the pigs infected with VR-2385 in
2001 was used to re-isolate the virus followed by two
subsequent passages in MARC-145 cells to produce the virus
stock of VR-2385 for this study. PRRSV isolate NC16845b
with a RFLP pattern 1-18-2 was isolated in 2006 from a
clinically affected 9-week-old pig with systemic PCVAD
from a group of pigs from North Carolina with a history of
severe respiratory disease in 50% of the pigs and approx-
imatley 20% mortality in the group (Gauger et al., 2012). The
passage 2 virus of the original isolate was used to
experimentally infect a set of PRRSV-free conventional pigs
(data not shown) and the lung tissues from these pigs
collected two weeks after infection were used for re-
isolation of the NC16845b virus followed by two subsequent
passages in MARC-145 cells to produce the NC16845b virus
stock for this study. The two inocula were separated in
different aliquots, stored at 80 8C, and virus of the same lot
was used for all batches of pigs. On dpi 0, CoI-92-2a, CoI-92-
2b, PRRSV-I-92, and B3-PRRSV-I-92 groups received 2 ml of
PRRSV isolate VR-2385 at a dose of 105.0median tissue
culture infective dose (TCID50) per ml. All pigs in groups CoI-
06-2a, CoI-06-2b, PRRSV-I-06, and B3-PRRSV-I-06 received
2 ml of PRRSV isolate NC16845b at a dose of 105.0 TCID50 per
ml. Inoculation was intranasal by holding the pig in the
upright position and slowly dripping 1 ml of the inoculum
into each nostril using a 3 ml syringe (Fisher Scientiﬁc, Inc.).
2.2.2. PCV2
Two different PCV2 subtypes were used for the
inoculation of pigs. Pigs in groups CoI-92-2a and CoI-06-
2a were inoculated with the PCV2a isolate 40895, which
was recovered from an Iowa farm in 1998 (Fenaux et al.,
2000) and has been well characterized genetically (Fenaux
et al., 2000) and in the conventional speciﬁc pathogen free
(SPF) pig model (Opriessnig et al., 2003, 2004a). Both
PCV2a and PCV2b viruses were produced as described
previously (Opriessnig et al., 2008b) and used for inocula-
tion in this study at a titer of 104.0 TCID50 per ml. Pigs in
groups CoI-92-2b and CoI-06-2b were inoculated with
PCV2b isolate NC16845 which was isolated in 2006 from a
pig farm in North Carolina (Opriessnig et al., 2008b). Both,
PCV2b NC16845 and PRRSV NC16845b originated from the
same tissues. The PCV2 groups were inoculated intrana-
sally (3 ml) and intramuscularly (2 ml) with their respec-
tive PCV2 subtype by injecting 2 ml of the inoculum
intramuscularly into the right neck area and 3 ml (1.5 ml
per nostril) intranasally by holding the pig in the upright
position and slowly dripping 1.5 ml of the inoculum into
each nostril using a 3 ml syringe (Fisher Scientiﬁc, Inc.).
2.3. Leukogram
EDTA-treated blood samples were analyzed for white
blood cells using a multispecies hematology instrument
(Hemavet HV950FS, Drew Scientiﬁc, Inc.). The white blood
cell (WBC) count was reported as actual numbers of
neutrophils, lymphocytes and total WBC per ml of whole
blood. In addition to WBC, a ratio was determined between
the total neutrophil count and the total lymphocyte count
reported as the N/L ratio. Values from negative control pigs




Serum samples from all pigs were also tested for the
presence of anti-PRRSV antibodies by a commercial PRRSV
ELISA (HerdChek PRRS virus antibody test kit 2XR, IDEXX
Laboratories Inc. Westbrook, MA, USA), according to the
instructions of the manufacturer. Samples were considered
positive if the calculated S/P ratio was equal to 0.4 or
greater.
2.4.2. PCV2
All serum samples were tested for the presence of anti-
PCV2 IgG antibodies based on an open reading frame 2
(ORF2) ELISA (Nawagitgul et al., 2002). Samples were
considered positive if the calculated sample-to-positive (S/
P) ratio was equal to 0.2 or greater.
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2.4.3. Other viruses
On dpi 12, three samples were randomly chosen from
each group and room and tested for the presence of swine
inﬂuenza virus (SIV) antibodies by an in house nucleopro-
tein NS1 ELISA (Richt et al., 2006) and for the presence of
antibodies to porcine parvovirus (PPV) by hemagglutina-
tion inhibition (HI) assay (Mengeling et al., 1988).
2.5. Interferon gamma (IFN-g)
A commercial ELISA kit (Swine IFN-g; Invitrogen,
Camarillo, CA, USA) was used to detect and quantify
IFN-g concentrations in serum according to the instruc-
tions of the manufacturer.
2.6. Clinical evaluation
Following PRRSV/PCV2 coinfection, the pigs were
monitored daily for respiratory disease (dyspnea, sneezing,
coughing, nasal discharge). Rectal temperatures and
behavioral changes such as lethargy and inappetence/
anorexia were also recorded daily. The observers were
aware (not blinded) to the treatment status.
2.7. Quantitative real-time PCR
2.7.1. PRRSV RT-PCR
RNA extraction on serum collected at dpi 0, 3, 6, 9, and
12 was performed using a QIAamp viral RNA mini kit
(Qiagen, Valencia, CA, USA). The AgPATH-ID PRRSV multi-
plex reagent kit (Applied Biosystems, Foster City, CA, USA)
was used for the real-time, reverse transcriptase PCR (RT-
PCR) on each extracted RNA sample. All samples were run
in duplicate. Each PCR consisted of 8 ml template RNA and
17 ml of PCR master mix. The PCR master mix contained
12.5 ml of 2 RT-PCR buffer, 2.5 ml 10 PRRSV primer
probe mix, 1.25 ml 20 multiplex RT-PCR enzyme mix,
0.25 ml of ZenoRNA-01 internal control RNA and 0.5 ml
nuclease-free water. Each reaction included eight pro-
gressive 1:10 dilutions of a known copy number of PRRSV
to generate a standard curve for quantiﬁcation. Each plate
was run in the sequence detection system (GeneAmp 5700
Sequence Detection System, Applied Biosystems) using the
AgPATH-ID company speciﬁc conditions (10 min at 45 8C,
10 min at 95 8C, followed by 40 cycles of 2 s at 97 8C and
40 s at 60 8C). Samples were considered negative when no
signal was observed within the 40 ampliﬁcation cycles.
2.7.2. PCV2 ORF1-based PCR
DNA extraction on serum collected on dpi 0, 3, 6, 9, and
12 days was performed using the QIAamp DNA blood mini
kit (Qiagen, Valencia, CA, USA) and subsequently used for
detection of PCV2 DNA by quantitative real-time PCR
utilizing primers and a probe designed for PCV2 ORF1 as
described (Opriessnig et al., 2003). The real-time PCR
reaction consisted of a 25 ml PCR mixture containing
12.5 ml commercially available master mix (TaqMan1
Universal PCR master mix, Applied Biosystems by Life
Technologies), 2.5 ml DNA, 1 ml (0.4 mM) of each primer,
and 0.5 ml (0.2 mM) probe. The reaction was run in a 7500
Fast Real-Time PCR system (ABI, Foster City, CA, USA)
under the following conditions: 50 8C for 2 min, 95 8C for
10 min, followed by 40 cycles of 95 8C for 15 s and 60 8C for
1 min. All samples were run in duplicate. Serial dilutions of
a recombinant PCV2 DNA clone were included on each
plate to generate a standard curve. Viral concentrations
were expressed as the DNA copy numbers per ml of
sample. Samples were considered negative when no signal
was observed within the 40 ampliﬁcation cycles.
2.7.3. PCV2a/b ORF2-based differential PCR
All DNA extracts were also tested for presence of PCV2a
and PCV2b DNA by utilizing a forward primer (50-
GCAGGGCCAGAATTCAACC-30), a reverse primer (50-
GGCGGTGGACATGATGAGA-30), a probe speciﬁc for PCV2a
(50-Cal Fluor Orange 560-GGGGACCAACAAAATCTCTA-
TACCCTTT-BHQ-30), and a probe speciﬁc for PCV2b (50-
Quasar 670-CTCAAACCCCCGCTCTGTGCCC-BHQ-30), which
were designed in the PCV2 ORF2 as described (Opriessnig
et al., 2010). The multiplex real-time PCR reaction
consisted of a total volume of 25 ml containing 12.5 ml
of the commercially available master mix (Applied
Biosystems), 5 ml DNA, 0.4 mM of each primer, and
0.2 mM of each probe. All samples were run in duplicate.
The reactions were carried out under the following
conditions: 50 8C for 2 min, 95 8C for 10 min, followed by
40 cycles of 95 8C for 15 s and 60 8C for 1 min. The
sensitivity and speciﬁcity of the real-time PCR reaction was
evaluated using known PCV2a and PCV2b isolates as well
as PPV, PRRSV, and PCV type 1 (PCV1) isolates. Samples
were considered negative when no signal was observed
within the 40 ampliﬁcation cycles.
2.8. Sequencing
Open reading frame (ORF) 5 of one PRRSV RT-PCR
positive pig in each group was sequenced on dpi 12 as
previously described (Gauger et al., 2012).
2.9. Necropsy
On dpi 12, all pigs were humanely euthanized by
intravenous pentobarbital overdose (Fatal-Plus1 Vortech
Pharmaceutical, Ltd., Dearborn, MI, USA). Macroscopic
lung lesions were estimated based on the percentage of the
lung surface affected by pneumonia ranging from 0 to 100%
(Halbur et al., 1995b). The scoring system was based on the
approximate volume that each lung lobe contributes to the
entire lung: the right cranial lobe, cranial part of the left
cranial lobe, and the caudal part of the left cranial lobe
contribute 10% each to the total lung volume, the accessory
lobe contributes 5%, and the right and left caudal lobes
contribute 27.5% each (Halbur et al., 1995b). Additionally,
lymph node size was scored ranging from 0 (normal) to 3
(four times the normal size) (Opriessnig et al., 2006). Lungs
were insufﬂated with ﬁxative as previously described
(Halbur et al., 1995b). Sections of lymph nodes (tracheo-
bronchial, mesenteric, mediastinal, superﬁcial inguinal,
and external iliac), tonsil, thymus, ileum, kidney, colon,
spleen, heart, liver, and brain were collected at necropsy
and ﬁxed in 10% neutral-buffered formalin and routinely
processed for histological examination.
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2.10. Histopathology
Microscopic lesions were evaluated independently by
two veterinary pathologists (TO, PCG) blinded to the
treatment status. Sections of lung were scored for the
presence and severity of interstitial pneumonia ranging from
0 (normal) to 6 (severe, diffuse) (Halbur et al., 1995b).
Sections of heart, liver, kidney, ileum, colon and brain were
evaluated for the presence of lymphohistiocytic inﬂamma-
tion and scored from 0 (none) to 3 (severe). Lymphoid tissues
including lymph nodes (trachea-bronchial, mediastinal,
mesenteric, external iliac and superﬁcial inguinal), tonsil,
spleen and thymus were evaluated for the presence of
lymphoid depletion ranging from 0 (normal) to 3 (severe)
and histiocytic inﬂammation and replacement of follicles
ranging from 0 (normal) to 3 (severe) (Opriessnig et al., 2006).
2.11. Immunohistochemistry
2.11.1. PRRSV
Detection of PRRSV-speciﬁc antigen was performed by
IHC staining on lung sections as previously described
(Halbur et al., 1995a). Sections were scored for presence of
PRRSV antigen independently by two veterinary pathol-
ogists (TO, PCG) blinded to the treatment groups.
2.11.2. PCV2
IHC for detection of PCV2-speciﬁc antigen was per-
formed on sections of lung, lymph nodes (tracheobronchial,
mediastinal, mesenteric, superﬁcial inguinal and external
iliac), tonsil, spleen, thymus and small intestine using a
rabbit polyclonal antiserum (Sorden et al., 1999). Sections
were scored for presence and amount of PCV2 antigen
independently by two veterinary pathologists (TO, PCG)
blinded to the treatment groups. If the results obtained by
the two pathologists on a certain tissue differed, the mean of
the two scores was used. PCV2 scores ranged from 0 (no
antigen) to 3 (more than 50% of the lymphoid follicles
contain cells with PCV2-antigen staining) (Opriessnig et al.,
2006). Any tissue or tissue pool with detectable staining was
given at least a score of 1. For the purpose of determining
prevalence rates, a score of 0 was considered negative and
scores of 1, 2 and 3 were considered positive.
2.12. Statistical analysis
For data analysis, JMP1 software version 8.0.1and SAS1
software version 9.2.0 (both SAS Institute, Cary, NC, USA)
were used. Summary statistics were calculated for groups
to assess the distributional property and data that were not
distributed normally (PCR data) were log transformed
prior to analysis. As log transformation can only be applied
to numbers above 0, a constant number (1) was added to
each number in the data set prior to log transformation. A
linear mixed model with the random effects ‘‘Source’’
(Source A: B1 and B2 and Source B: B3) and ‘‘Batch’’ (B1, B2,
B3, nested within ‘‘Source’’) and the ﬁxed effects ‘‘PRRSV
strain’’ (none, VR-2385, NC16845b) and ‘‘PCV2 subtype’’
(none, PCV2a, PCV2b) was used ﬁrst on all outcomes. From
this, it was determined that the random effect ‘‘Source’’
contributed to the overall variation whereas ‘‘Batch’’ did
not. To decrease the heterogeneity of the animals in the
analysis, all data obtained from the second source, B3, were
removed from the analysis but were provided as supple-
mental information throughout the ‘‘Results’’ and Tables.
The ﬁnal model to analyze continuous data collected over
time (rectal temperatures, blood cell counts, log trans-
formed PCV2 and PRRSV genomic copies, and ELISA S/P
ratios) was a repeated measures analysis of variance
(ANOVA), where PRRSV strain, PCV2 subtype, DPI and their
interactions were the ﬁxed effects and pig was the subject
of repeated measures. Compound symmetry variance-
covariance structure was used to model the within pig
correlation. A one-way ANOVA was used to analyze cross-
sectional data (macroscopic and microscopic lung lesions)
where PRRSV strain, PCV2 subtype, and their interaction
were the ﬁxed effects. Differences among the interacting
groups (PRRSV strain  PCV2 subtype) in the repeated
measures ANOVA or the one-way ANOVA were assessed
using Tukey’s t-test. A p-value of less than 0.05 was
considered signiﬁcant. Differences in prevalence of PRRSV
and PCV2 antigen between groups (IHC staining) were
determined by Fisher’s exact test.
3. Results
3.1. Clinical presentation
Mild, transient lethargy and inappetence were observed
in all inoculated groups, although coughing or sneezing was
not a feature. Pigs in all inoculated groups regardless of
coinfection status developed a transient to persistent fever
ranging from 40.0 8C to 41.8 8C between dpi 3 and dpi 12. The
mean rectal temperature time by group interaction after
inoculation was signiﬁcant (P < 0.05). All six inoculated
groups had rectal temperatures signiﬁcantly higher than the
negative controls at dpi 6 and dpi 9. By dpi 12, the mean
group rectal temperatures in the PRRSV-I-92, PRRSV-I-06,
CoI-92-2a, CoI-92-2b and CoI-06-2a groups were signiﬁ-
cantly (P < 0.05) higher compared to the negative controls.
When the effect of ‘‘PRRSV strain’’ was evaluated across
groups, no differences were found. Compared to pigs
infected with PRRSV alone, coinfected pigs had higher mean
rectal temperatures at dpi 3, 6 and 9. When the effect ‘‘PCV2
subtype’’ was evaluated among coinfected groups, PCV2a
pigs had signiﬁcantly (P < 0.01) higher rectal temperatures
on dpi 9 compared to PCV2b pigs (data not shown). B3 pigs
(B3-PRRSV-I-92 and B3-PRRSV-I-06) had similar rectal
temperatures as B2 (PRRSV-I-92 and PRRSV-I-06) pigs.
3.2. Whole blood counts
Hematology results are summarized in Table 2. There
was an effect of ‘‘PRRSV strain’’ on white blood cell counts
at dpi 3 with pigs infected with NC16845b having
signiﬁcantly (P = 0.03) higher levels of white blood cells
compared to pigs infected with VR-2385 (10.5  0.9 versus
8.1  0.5). Also, there was a signiﬁcant effect of ‘‘PCV2’’
(P < 0.05): PCV2-infected pigs had higher levels of white
blood cells at dpi 9 and 12 compared to non-PCV2-infected
pigs (17.1  0.9 versus 9.4  0.6 and 20.3  1.0 versus
14.5  1.2). There was no effect of ‘‘PRRSV strain’’ on numbers
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of neutrophils; however, there was a signiﬁcant effect of
‘‘PCV2’’ on mean group neutrophil counts at dpi 6, 9, and 12
with PCV2-infected pigs having elevated levels compared to
pigs not infected with PCV2 (5.3  0.4 versus 3.1  0.3,
10.0  0.6 versus 3.4  0.3, and 11.9  6.1 versus 6.1  0.9,
respectively). Differences in mean group lymphocyte counts
were only observed on dpi 9 (Table 2) and there was an effect
of PRRSV strain (P = 0.048): pigs infected with NC16845b had
lower levels of lymphocytes compared to pigs infected with
VR-2385 (3.9  0.3 versus 5.1  0.5). Additionally, pigs
coinfected with PCV2 had higher levels of lymphocytes
(P = 0.016) compared to pigs infected with PRRSV alone
(4.8  0.3 versus 3.0  0.3) suggesting an effect of ‘‘PCV2’’.
3.3. Antibody levels
3.3.1. Anti-PRRSV-IgG antibody levels
All pigs in all groups were negative for PRRSV-speciﬁc
antibodies at 0 dpi and negative control pigs remained
negative for anti-PRRSV antibody throughout the study.
Prevalence and group mean S/P ratios are summarized in
Table 3. Overall, there was a signiﬁcant effect of ‘‘PRRSV
strain’’ and ‘‘PCV2’’ on the anti-PRRSV antibody response at
dpi 9. Speciﬁcally, pigs infected with VR-2385 had a
signiﬁcantly (P = 0.017) higher anti-PRRSV antibody
response compared to those infected with NC16845b.
Similarly, coinfected pigs had signiﬁcantly (P = 0.028)
higher anti-PRRSV S/P ratios compared to pigs singularly
infected with PRRSV. There was no effect of ‘‘PCV2
subtype’’ on the magnitude of the anti-PRRSV-antibody
response among coinfected groups.
3.3.2. Anti-PCV2-IgG antibody levels
All pigs in B1 and B2 were negative for PCV2-speciﬁc
anti-IgG antibodies at 0 dpi and the negative controls and B2
pigs remained PCV2 seronegative throughout the trial. In the
PCV2 coinfected groups, seroconversion was observed at dpi
9. The prevalence and mean group anti-PCV2-IgG S/P ratios
Table 2
Mean group leukocyte values (1000/ml of whole blood except for ratios) in the different treatment groups on days post-inoculation (dpi) 0, 3, 6, 9 and 12.
Data obtained from B3-PRRSV-I-92 and B3-PRRSV-I-06 pigs (gray shaded area) were not included in the analysis.
Group Hematologya 0 3 6 9 12
Negative controls (n = 8) WBC 8.6  1.0 6.0  0.7A 12.0  0.8 19.8  2.8A 17.8  0.9A,B
Neutrophils 2.7  0.3 2.7  0.3 4.9  0.3 9.1  1.5A,B 7.7  0.7A,B
Lymphocytes 4.1  0.3 2.4  0.3 4.9  0.6 6.4  0.4A,B 7.2  0.3
N/L ratio 0.6  0.3 1.1  0.1 1.1  0.1A 1.5  0.2A,B 1.1  0.2A
CoI-92-2a (n = 9) WBC 13.6  2.1 8.3  0.8A,B 8.4  1.2 17.5  1.7A.B 19.5  1.3A,C
Neutrophils 5.5  1.3 4.6  0.8 4.5  0.7 10.2  1.0A 12.0  0.8B,C
Lymphocytes 6.0  0.9 2.5  0.3 2.7  0.6 4.7  0.6A,B,C 5.0  0.6
N/L ratio 1.0  0.2 2.1  0.5 1.9  0.3A,B 2.3  0.2A 2.6  0.3B
CoI-92-2b (n = 9) WBC 12.1  1.6 8.6  0.8A,B 10.9  1.1 20.2  1.4A 23.5  2.0A
Neutrophils 4.6  1.1 4.7  0.7 6.2  0.7 11.3  0.8A 14.1  1.1C
Lymphocytes 5.7  0.7 2.7  0.2 3.4  0.4 6.6  0.9A 6.9  1.2
N/L ratio 0.9  0.2 1.8  0.3 1.9  0.2A,B 1.9  0.2A,B 2.4  0.3B,C
CoI-06-2a (n = 9) WBC 10.8  0.9 8.7  1.0A,B 9.8  0.7 14.8  2.1A,B 18.7  1.7A,B
Neutrophils 3.4  0.3 3.9  0.5 4.0  0.3 4.7  0.6A,B,C 9.9  0.8A,B,C
Lymphocytes 5.3  0.6 3.4  0.5 3.4  0.4 4.0  0.5B,C 6.4  0.8
N/L ratio 0.7  0.4 1.2  0.2 1.3  0.1A,B 2.3  0.3A 1.7  0.2A,B,C
CoI-06-2b (n = 9) WBC 12.8  2.4 10.4  1.5A,B 11.7  1.7 16.0  1.6A,B 19.5  2.0A,B
Neutrophils 6.0  1.8 5.3  0.8 6.6  1.1 9.8  1.2A,B 11.7  1.6C,B
Lymphocytes 5.1  0.7 2.8  0.3 3.4  0.5 4.1  0.5A,B,C 6.1  0.8
N/L ratio 0.9  0.5 2.0  0.2 2.1  0.3B 2.5  0.1A 2.0  0.2A,B,C
PRRSV-I-92 (n = 4) WBC 7.8  0.9 6.6  0.6A 6.9  1.0 9.1  0.8B 16.4  1.3A,B
Neutrophils 3.0  0.6 1.8  0.2 2.6  0.4 3.8  0.6B,C 7.4  1.3A,B
Lymphocytes 4.1  0.6 2.7  0.3 2.5  0.6 2.6  0.2C 6.0  1.1
N/L ratio 0.7  0.1 0.7  0.0 1.3  0.5A,B 1.4  0.1A,B 1.3  0.2A,C
PRRSV-I-06 (n = 5) WBC 10.6  0.4 13.9  2.3B 10.4  1.5 9.5  0.9B 13.3  1.7B
Neutrophils 3.4  0.3 5.6  1.7 3.4  0.5 3.1  0.2C 5.1  1.1A
Lymphocytes 4.8  0.6 2.6  0.4 4.2  1.0 3.3  0.4C 4.5  0.4
N/L ratio 0.7  0.1 2.1  0.5 1.0  0.3A,B 1.0  0.1B 1.1  0.2A
B3-PRRSV-I-92 (n = 5) WBC 12.1  2.1 11.0  1.1 11.1  1.0 14.6  2.0 21.6  1.8
Neutrophils 5.9  1.4 4.8  2.6 4.1  0.6 8.3  1.8 13.8  1.6
Lymphocytes 3.7  0.5 2.6  0.8 2.1  0.4 2.3  0.4 4.0  0.8
N/L ratio 1.6  0.3 1.9  0.3 2.1  0.2 3.6  0.6 3.6  0.4
B3-PRRSV-I-06 (n = 4) WBC 13.3  1.2 13.4  0.6 10.9  0.8 14.0  1.2 17.9  3.2
Neutrophils 5.6  1.1 4.3  0.5 4.2  0.7 6.0  1.0 9.1  2.1
Lymphocytes 5.3  1.0 2.7  0.7 2.8  0.3 2.5  0.2 3.7  0.3
N/L ratio 1.2  0.2 2.6  1.0 1.5  0.2 2.5  0.5 2.5  0.6
Different superscripts (A, B, C) within columns indicate signiﬁcant (P < 0.05) differences among groups.
a WBC: white blood cells; N/L ratio: neutrophil to lymphocyte ratio.
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are summarized in Table 4. There was no effect of ‘‘PRRSV
strain’’ or ‘‘PCV2 subtype’’ on the magnitude of the anti-
PCV2-antibody response. B3 pigs were seropositive for PCV2
at the time of arrival (mean PCV2 ELISA S/P ratio:
1.58  0.09) and the S/P ratios remained at a similar level
for the duration of the study (data not shown).
3.3.3. Other viruses
At termination of the study, pigs randomly selected
from each batch tested negative for antibodies against PPV,
SIV H1N1 and SIV H3N2 (data not shown).
3.4. IFN-g levels
Prevalence of IFN-g positive samples and mean group
IFN-g concentrations are summarized in Table 5. There
was no effect of ‘‘PRRSV strain’’ or ‘‘PCV2’’ on the IFN-g
levels and no differences were found among groups;
however, analysis of an effect of ‘‘PCV2 subtype’’ among
coinfected groups revealed that on dpi 6, PCV2b-inocu-
lated pigs had signiﬁcantly (P = 0.028) higher levels of IFN-
g compared to PCV2a-inoculated pigs (0.46  0.17 pg/ml
versus 0.06  0.05 pg/ml).
3.5. PRRSV and PCV2 viremia
3.5.1. Prevalence and amount of PRRSV RNA
All pigs were negative for PRRSV-RNA in serum at 0 dpi
and the negative controls remained negative for PRRSV
RNA throughout the study. The prevalence of PRRSV RNA
positive pigs and group mean genomic copy numbers/ml
are summarized in Table 6. Sequencing of the ORF5 gene of
PRRSV and comparison with the original inocula conﬁrmed
that the correct PRRSV isolates were present in the
Table 3
Prevalence of anti-PRRSV antibodies and mean group sample-to-positive (S/P) ratios in the different treatment groups on days post-inoculation (dpi) 0, 3, 6,
9 and 12. Data presented as prevalence (mean S/P ratio  SE). Data obtained from B3-PRRSV-I-92 and B3-PRRSV-I-06 pigs (gray shaded area) were not included
in the analysis.
Group 0 3 6 9 12
Negative controls 0/8 (0.01  0.00) 0/8 (0.02  0.00) 0/8 (0.02  0.00) 0/8 (0.02  0.01)A 0/9 (0.02  0.00)A
CoI-92-2a 0/9 (0.01  0.00) 0/9 (0.01  0.00) 0/9 (0.03  0.01) 7/9 (0.74  0.19)B 9/9 (0.84  0.09)B
CoI-92-2b 0/9 (0.02  0.01) 0/9 (0.01  0.00) 0/9 (0.02  0.01) 6/9 (0.82  0.26)C 9/9 (0.98  0.24)B
CoI-06-2a 0/9 (0.08  0.07) 0/9 (0.08  0.07) 0/9 (0.08  0.06) 4/9 (0.40  0.08)A,B 7/9 (0.70  0.11)B
CoI-06-2b 0/9 (0.01  0.00) 0/9 (0.01  0.01) 0/9 (0.01  0.00) 6/9 (0.52  0.08)A,B 6/9 (0.68  0.12)B
PRRSV-I-92 0/4 (0.01  0.00) 0/4 (0.01  0.00) 0/4 (0.00  0.00) 2/4 (0.35  0.06)A,B 4/4 (0.83  0.13)B
PRRSV-I-06 0/5 (0.02  0.00) 0/5 (0.01  0.00) 0/5 (0.00  0.00) 0/5 (0.08  0.03)A,B 2/5 (0.36  0.19)B
B3-PRRSV-I-92 0/5 (0.01  0.00) 0/5 (0.01  0.00) 0/5 (0.00  0.00) 3/5 (0.56  0.02) 5/5 (0.77  0.21)
B3-PRRSV-I-06 0/4 (0.02  0.00) 0/4 (0.01  0.00) 0/4 (0.01  0.00) 2/4 (0.20  0.12) 1/4 (0.30  0.14)
Different superscripts (A, B, C) within columns indicate signiﬁcant (P < 0.05) differences in mean group S/P ratios among groups.
Table 4
Prevalence of anti-PCV2 IgG antibodies and mean group sample-to-positive (S/P) ratios in the different treatment groups except PRRSV-I-92 and PRRSV-I-06
on day post-inoculation (dpi) 0, 3, 6, 9 and 12. Data presented as prevalence (mean S/P ratio  SE). Grey shaded areas indicate the presence of PCV2
seropositive pigs (S/P ratio > 0.2) within a treatment group.
Group 0 3 6 9 12
Negative controls 0/8 (0.01  0.01) 0/8 (0.01  0.01) 0/8 (0.03  0.05) 0/8 (0.15  0.16)A 0/8 (0.00  0.0)A
CoI-92-2a 0/9 (0.00  0.01) 0/9 (0.02  0.03) 0/9 (0.02  0.01) 4/9 (0.17  0.04)B 5/9 (0.22  0.05)B
CoI-92-2b 0/9 (0.00  0.01) 0/9 (0.02  0.03) 0/9 (0.02  0.01) 0/9 (0.05  0.01)A,B 3/9 (0.16  0.03)A,B
CoI-06-2a 0/9 (0.02  0.02) 0/9 (0.06  0.08) 0/9 (0.03  0.01) 3/9 (0.13  0.03)A,B 7/9 (0.29  0.04)B
CoI-06-2b 0/9 (0.00  0.00) 0/9 (0.00  0.02) 0/9 (0.03  0.01) 2/9 (0.11  0.04)A,B 4/9 (0.26  0.06)B
Different superscripts (A, B) within columns indicate signiﬁcant (P < 0.05) differences in mean group S/P ratios among groups.
Table 5
Prevalence of IFN-g and mean group concentration (pg/ml) in the different treatment groups on day post-inoculation (dpi) 0, 3, 6, 9 and 12. Data presented
as prevalence (mean log10 group concentration  SE). Data obtained from B3-PRRSV-I-92 and B3-PRRSV-I-06 pigs (gray shaded area) were not included in the
analysis.
Group 3 6 9 12
Negative controls 0/8 1/8 (0.09  0.09) 0/8 (0.00  0.00) 1/8 (0.05  0.05)
CoI-92-2a 0/9 1/9 (0.03  0.03) 7/9 (1.16  0.30) 1/9 (0.27  0.27)
CoI-92-2b 0/9 2/9 (0.39  0.26) 6/9 (0.77  0.33) 2/9 (0.39  0.28)
CoI-06-2a 0/9 1/9 (0.09  0.09) 3/9 (0.46  0.24) 1/9 (0.17  0.17)
CoI-06-2b 0/9 4/9 (0.53  0.22) 6/9 (1.01  0.28) 2/9 (0.31  0.21)
PRRSV-I-92 0/4 0/4 0/4 1/4 (0.35  0.35)
PRRSV-I-06 1/5 (0.25  0.25) 1/5 (0.24  0.24) 1/5 (0.32  0.32) 1/5 (0.40  0.40)
B3-PRRSV-I-92 0/5 0/5 0/5 (0.03  0.01) 2/5 (0.70  0.49)
B3-PRRSV-I-06 0/4 1/4 (0.32  0.32) 0/4 0/4
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respective groups and rooms. When results were analyzed
for a possible effect of ‘‘PRRSV strain’’, a signiﬁcantly
(P < 0.05) higher amount of PRRSV RNA was detected in
pigs infected with VR-2385 at dpi 3 and 6 compared to pigs
infected with NC16845b (Fig. 1). When the pigs infected
with PRRSV alone were removed from the analysis,
coinfected pigs with NC16845b had signiﬁcantly higher
amounts of PRRSV RNA in serum compared to pigs infected
with VR-2385 on dpi 9 (6.49  0.10 versus 5.99  0.11) and
dpi 12 (6.24  0.08 versus 5.55  0.12), respectively. An effect
of ‘‘PCV2’’ or ‘‘PCV2 subtype’’ on PRRSV replication was not
evident.
3.5.2. Prevalence and amount of PCV2 DNA
All pigs were negative for PCV2-DNA in serum at 0 dpi
and the negative controls and B2 and B3 pigs remained
PCV2 DNA negative throughout the study (data not
shown). At dpi 3, 28/36 PCV2-inoculated pigs were positive
for PCV2-DNA, and all PCV2-inoculated pigs were positive
for PCV2-DNA by 6 dpi and remained positive until dpi 12.
The log10 group mean PCV2 DNA amounts are summarized
in Fig. 2. When results were analyzed for a possible effect of
‘‘PRRSV strain’’ it was found that there was a signiﬁcantly
higher amount of PCV2 DNA in pigs infected with VR-2385
(7.99  0.19) compared to pigs infected with NC16845b
(7.01  0.21) on dpi 12. There was a signiﬁcant effect of
‘‘PCV2 subtype’’ on dpi 3; groups infected with PCV2b had
signiﬁcantly higher amounts of PCV2 DNA in serum
compared to groups infected with PCV2a (4.63  0.40 versus
2.96  0.51, respectively). An effect of ‘‘PCV2 subtype’’ was
not evident in the later stages of infection.
3.5.3. PCV2 subtypes
All pigs in the PCV2a or PCV2b groups were correctly
infected with their respective subtype as determined by
multiplex real-time PCR (data not shown) and cross-
contamination between groups and rooms was not
detected.
Table 6
Prevalence of PRRSV and group mean log10 PRRSV genomic copies per ml in the different treatment groups on days post-inoculation (dpi) 3, 6, 9 and 12. Data
presented as prevalence (log10 PRRSV RNA  SE). Data obtained from B3-PRRSV-I-92 and B3-PRRSV-I-06 pigs (gray shaded area) were not included into the
analysis.
Group 3 6 9 12
Negative controls 0/8 (0.00  0.00)A 0/8 (0.00  0.00)A 0/8 (0.00  0.00)A 0/8 (0.00  0.00)A
CoI-92-2a 9/9 (5.44  0.23)B,D 9/9 (6.74  0.14)B 9/9 (6.63  0.05)B 9/9 (6.17  0.08)B
CoI-92-2b 9/9 (5.42  0.22)B,D 9/9 (6.93  0.16)B 9/9 (6.23  0.18)B 9/9 (5.76  0.22)B
CoI-06-2a 9/9 (4.66  0.16)B,C 9/9 (6.35  0.17)B,C 9/9 (6.93  0.12)B 9/9 (6.56  0.08)B
CoI-06-2b 9/9 (5.35  0.36)B,D 9/9 (6.53  0.28)B 9/9 (6.90  0.16)B 9/9 (6.76  0.14)B
PRRSV-I-92 4/4 (6.36  0.25)D 4/4 (7.45  0.18)B 4/4 (7.11  0.09)B 4/4 (7.11  0.16)B
PRRSV-I-06 3/5 (2.99  1.26)C 4/5 (4.82  1.47)C 5/5 (6.00  0.92)B 5/5 (6.25  0.02)B
B3-PRRSV-I-92 4/5 (4.52  1.14) 5/5 (7.47  0.12) 5/5 (7.43  0.14) 5/5 (7.28  0.09)
B3-PRRSV-I-06 4/4 (3.84  0.63) 3/4 (4.57  1.53) 4/4 (6.12  1.33) 4/4 (7.13  0.44)
Different superscripts (A,B,C,D) within columns indicate signiﬁcant (P < 0.05) differences in mean group S/P ratios among groups.
Fig. 1. Log10 transformed mean PRRSV RNA genomic copies (SE) in VR-2385 and NC16845b infected pigs regardless of coinfection status on day post-
inoculation (dpi) 0, 3, 6, 9 and 12. Signiﬁcant (P < 0.05) differences between groups within a dpi are indicated by asterisks. The lines indicate the linear trend for
pigs infected with VR-2385 (gray, dashed) or NC16845b (black, solid).
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3.6. Macroscopic lesions
Macroscopic lesions were characterized by mild-to-
moderate enlargement of lymph nodes (especially tra-
cheobrochiolar lymph nodes and mediastinal lymph
nodes) and mottled-tan lungs with varying degrees of
the lung surface affected by visible pneumonia lesions. The
group mean lung lesion severity scores are summarized in
Table 7 and were signiﬁcantly (P < 0.05) lower for negative
controls compared to all coinfected groups. There were no
signiﬁcant differences in lung lesions severity between the
negative controls and the pigs infected with PRRSV alone.
There was an effect of ‘‘PCV2’’ on the mean group
macroscopic lung lesion scores as evidenced by the
coinfected pigs having more severe macroscopic lung
lesions compared to pigs infected with PRRSV alone.
However, there was no effect of ‘‘PRRSV strain’’ or ‘‘PCV2
subtype’’ on the severity of the observed macroscopic lung
lesions.
3.7. Microscopic lesions
Lung tissues had multifocal-to-diffuse, mild-to-severe,
lymphohistiocytic interstitial pneumonia. The mean
microscopic lung lesion scores, which are summarized in
Table 7, were signiﬁcantly (P < 0.0001) lower in the
negative controls compared to the four coinfected groups;
however, the scores in the negative controls were not
signiﬁcantly lower than observed in the groups singularly
infected with PRRSV. There was a signiﬁcant effect of
‘‘PCV2’’ (P < 0.001) on microscopic lung lesions but there
was no effect of ‘‘PRRSV strain’’ or ‘‘PCV2 subtype’’ on the
severity of the observed microscopic lung lesions.
Lymphoid lesions were either not observed or were
characterized by mild depletion of follicles and minimal
granulomatous lymphadenitis in all coinfected groups.
Signiﬁcant differences in lymphoid lesion scores were not
observed among the groups (data not shown).
3.8. Prevalence of PRRSV and PCV2 antigens in tissues
3.8.1. PRRSV
All control pigs were negative for PRRSV antigen by IHC
on sections of lung. The prevalence of PRRSV antigen in
lung sections was 16/23 pigs in the NC16845b-inoculated
group (B3: 4/4 pigs) compared to 21/22 pigs in the VR-
2385-inoculated group (B3: 5/5 pigs). There were no
signiﬁcant differences in the prevalence rates of PRRSV
Fig. 2. Log10 transformed group mean PCV2 DNA amounts (SE) in the PCV2-PRRSV coinfected groups on day post-inoculation (dpi) 0, 3, 6, 9 and 12. Signiﬁcant
(P < 0.05) differences between groups within a dpi are indicated by different superscripts (A, B).
Table 7
Mean group macroscopic (percentage of lung surface affected by lesions)
and microscopic (interstitial pneumonia ranging from 0 = normal to
6 = severe, diffuse) lung lesions (mean group amount  SE). Data obtained
from B3-PRRSV-I-92 and B3-PRRSV-I-06 pigs (gray shaded area) were not
included in the analysis. Signiﬁcant (P < 0.05) differences between groups





Negative controls 0.1  0.1A 0.75  0.25A
CoI-92-2a 54.8  4.3B 4.44  0.24B
CoI-92-2b 56.3  4.5B 4.67  0.17B
CoI-06-2a 52.8  6.4B 4.78  0.32B
CoI-06-2b 48.7  4.7B,C 4.44  0.24B
PRRSV-I-92 31.8  8.3B,C 2.50  0.87A
PRRSV-I-06 4.3  2.0A,C 1.80  0.80A
B3-PRRSV-I-92 43.8  5.7 4.60  0.24
B3-PRRSV-I-06 25.8  10.2 4.00  0.71
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antigen in lungs between the virus-inoculated groups. The
prevalence of PRRSV antigen in lungs was independent of
‘‘PRRSV strain’’ or ‘‘PCV2 subtype’’.
3.8.2. PCV2
All control pigs and all B2 and B3 pigs were negative for
PCV2 antigen by IHC. Low-to-high amounts of PCV2-
antigen in lung sections were detected in 8/9 CoI-92-2a
pigs, 7/9 CoI-92-2b pigs, 8/9 CoI-06-2a pigs and in 4/9 CoI-
06-2b pigs which corresponds to16/18 PCV2a-inoculated
pigs and 11/18 PCV2b-inoculated pigs. Moreover, PCV2
antigen was detected in 15/18 VR-2385-inoculated pigs
and in 12/18 NC16845b-inoculated pigs. The prevalence of
PCV2 antigen in lung tissues was independent of ‘‘PRRSV
strain’’ or ‘‘PCV2 subtype’’. In lymphoid tissues, low-to-
high amounts of PCV2 antigen were detected in 8/9 CoI-92-
2a pigs, 7/9 CoI-92-2b pigs, 8/9 CoI-06-2a pigs and in 5/9
CoI-06-2b pigs which corresponds to 16/18 pigs inoculated
with PCV2a and 12/18 pigs inoculated with PCV2b, as well
as 13/18 pigs inoculated with NC16845b and 15/18 pigs
inoculated with VR-2385. The prevalence of PCV2 antigen
in lymphoid tissues was independent of ‘‘PRRSV strain’’ or
‘‘PCV2 subtype’’.
4. Discussion
The objective of this study was to characterize the
infection dynamics and pathogenicity of two different type
2 PRRSV isolates recovered from pigs in 1992 and 2006 in a
conventional pig model. To mimic ﬁeld conditions where
coinfections frequently occur, the pigs were concurrently
infected with either PCV2a or PCV2b. The effect of each
PRRSV isolate was also evaluated in singularly inoculated
pigs. However, due to limitations in numbers of available
pigs from the source herd, the experiments with singularly
PRRSV-inoculated groups were conducted separately but
under the same study conditions, using the same inocula
and assays to analyze the samples.
The PRRSV isolate VR-2385 used in this experiment has
been well-characterized in the CDCD and the conventional
pig models and is considered a relatively highly pathogenic
PRRSV isolate from the 1990s (Halbur et al., 1995b, 1996;
Meng et al., 1996). In contrast, NC16845b represents a
more recent PRRSV isolated from an outbreak of respira-
tory disease on a farm characterized by high morbidity and
mortality in 2006 (Gauger et al., 2012). The ORF2-7
sequence homology between VR-2385 (GenBank accession
PRU20788 and PRU03040) and NC16845b (GenBank
accession HQ699067) was approximately 90.4%. The
ORF5 region demonstrated the least nucleotide and amino
acid homology at 87.4% and 87.1%, respectively (Gauger
et al., 2012).
In the past, dual infections with PRRSV and porcine
respiratory coronavirus (PRCV) or PRRSV and SIV were
studied using conventional pigs (Van Reeth et al., 1996)
and gnotobiotic pigs (Van Reeth and Nauwynck, 2000) and
in general disease was found to be more pronounced in
dually inoculated pigs. Interestingly, in gnotobiotic pigs
the effect of the coinfection appeared additive rather than
synergistic (Van Reeth and Nauwynck, 2000). More recent
studies have shown that PRRSV modiﬁes the innate
immune response, induces immunosuppression and
enhances the inﬂammatory response to PRCV in pigs (Jung
et al., 2009; Renukaradhya et al., 2010). In another study,
dual infection of speciﬁc pathogen-free pigs with PRRSV
and pseudorabies virus (PRV) resulted in more severe
clinical signs and increased pneumonia in pigs inoculated
with both viruses compared to pigs infected with PRRSV or
PRV alone (Shibata et al., 2003). It is also well recognized
that PCV2 replication is enhanced by concurrent PRRSV
infection in both CD and conventional pigs compared to
singularly inoculated pigs (Allan et al., 2000; Rovira et al.,
2002). To the authors’ knowledge, the pathogenicity of
genetically different PRRSV isolates in the presence of
concurrent viral infection has not been evaluated in vivo.
The combination of PRRSV and PCV2 is one of the most
common coinfections associated with swine respiratory
disease under ﬁeld conditions (Dorr et al., 2007; Pallare´s
et al., 2002). Both PRRSV isolates used in the current study
were isolated from ﬁeld cases of high mortality and
experimental infection of pigs with PRRSV VR-2385 has
resulted in severe lesions and high levels of viremia
(Halbur et al., 1995b, 1996). The two PCV2 isolates were
initially recovered from typical ﬁeld cases of PCVAD in
Iowa and North Carolina and have been characterized in
the conventional pig model side by side without identiﬁ-
able differences between PCV2 subtypes (Opriessnig et al.,
2008b; Sinha et al., 2011). In the current study, clinical
disease in the treatment groups was characterized by
variable numbers of infected pigs experiencing transient,
mild lethargy, mild respiratory disease and inappetence.
Coinfected groups had signiﬁcantly higher mean rectal
temperatures compared to pigs infected with PRRSV alone
and the negative controls. Interestingly, when organized
by coinfection status and analyzed by PCV2 subtype, pigs
inoculated with PCV2a had signiﬁcantly higher mean
group rectal temperatures compared to pigs inoculated
with PCV2b on dpi 9 which was associated with an anti-
PCV2-antibody response in 38.9% (7/18) of the PCV2a-
inoculated pigs on dpi 9 whereas a delayed antibody
response was seen in PCV2b- inoculated pigs (11.1%; 2/18).
It is well documented that pathogenic differences
between type 2 PRRSV isolates exist (Halbur et al.,
1995b, 1996). The uniqueness of the current study is the
utilization of two temporally and genetically different
PRRSV isolates both from cases of high morbidity and
mortality in the ﬁeld but isolated 15 years apart. In a
separate in vitro study comparing phenotypic traits of the
two PRRS viruses, NC16845b demonstrated reduced
growth characteristics compared to VR-2385 (Gauger
et al., 2012). NC16845b plaque sizes were slightly smaller
than VR-2385 and the peak viral titer demonstrated by
NC16845b was approximately 13-fold lower than the VR-
2385 peak titer. This is in contrast to the in vivo growth
characteristics demonstrated in this report. There were
clear differences in initial replication between the two
PRRSV isolates used in this study. The VR-2385-inoculated
pigs had signiﬁcantly higher levels of PRRSV RNA in serum
on dpi 3 and 6. Moreover, NC16845b replicated at higher
levels at dpi 9 and dpi 12 compared to VR-2385 which was
associated with signiﬁcantly lower levels of lymphocytes
at dpi 9 and a signiﬁcantly lower N/L ratio at dpi 12. These
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results suggest that highly pathogenic PRRSVs may
replicate more efﬁciently in vivo in contrast to their
decreased growth properties in vitro as previously
suggested (Johnson et al., 2004; Wang et al., 2008). This
is further supported by the data obtained from the pigs
infected with PRRSV alone (B2 and B3) which clearly show
an increase in replication in pigs infected with NC16845b
in the later stages of the in vivo study.
Similar to other PCV2-PRRSV coinfection studies (Allan
et al., 2000; Harms et al., 2001), macroscopic and
microscopic lesions in coinfected groups were enhanced
compared to pigs singularly infected with PRRSV. Recently,
it has been shown that pigs infected with VR-2385 had
signiﬁcantly prolonged (until 70 DPI) PCV2 viremia and
shedding in PRRSV-PCV2 coinfected pigs (Sinha et al.,
2011). A similar approach using PRRSV NC16845b, which
replicated differently from VR-2385 in the early stages of
infection, could potentially offer new insights on viral
interactions in pigs. In the current study, PCV2b replication
was signiﬁcantly up-regulated shortly after initiation of
the study at dpi 3 compared to PCV2a. Furthermore, the
CoI-92-2b group had signiﬁcantly higher quantities of
PCV2b in the serum compared to CoI-06-2a (dpi 3 and 12)
and CoI-06-2b (dpi 12) which was associated with a higher
prevalence of PCV2 antigen in tissues (93.8% versus 75.0%)
indicating a synergistic relationship between PRRSV-1992
(VR-2385) and PCV2. Unlike previous studies where the
average trial length ranged from 21 to 32 days (Allan et al.,
2000; Rovira et al., 2002), this trial was terminated at dpi
12 to evaluate PRRSV-induced lung lesions which tend to
be most severe between dpi 10 and dpi 14. It remains
unknown if the observed trend would have resulted in a
difference in clinical disease in the later stages of infection.
As expected, and similar to a previous study (Yu et al.,
2007), the pathological lesions associated with PCV2 were
either not present or they were mild; however, PCV2
antigen was detected in most tissues in coinfected pigs. In
this study, PCV2 naı¨ve pigs were utilized, thus the
relevance of the model to actual ﬁeld situations is limited
considering the majority of young pigs have high levels of
passively acquired anti-PCV2 antibodies (Opriessnig et al.,
2004b). Therefore, the impact of anti-PCV2 immunity on
the PCV2 infection could not be ascertained in the
experiment; however, this was not a major concern as
we know from several experiments that pigs with
passively derived antibodies, although protected from
clinical PCV2 associated disease, can still be infected with
PCV2 (McKeown et al., 2005; Opriessnig et al., 2008a).
Therefore, we believe that a PCV2 naı¨ve pig model
increases the ability to identify trends and associations
between PRRSV and PCV2.
In the current study, PRRSV-PCV2 coinfection was
administered intranasally on the same day. This model of
simultaneous dual inoculation does not fully mimic the
population dynamics due to the variability in timing of
exposure to these two pathogens within and between
herds in ﬁeld situations. On many conventional farms,
endemic exposure and seroconversion to PRRSV often
occurs earlier than exposure to PCV2. Infection of pigs with
PRRSV prior to PCV2 may contribute to the manifestation
of more severe PCV2-induced clinical disease and lesions.
PRRSV is immunosuppressive, primarily infecting porcine
alveolar macrophages (Drew, 2000), which decreases the
pig’s ability to clear subsequent infections. In contrast,
prior PRRSV infection may induce an immunostimulatory
effect on the host immune response that serves to enhance
PCV2 replication and lesions (Krakowka et al., 2001).
It is possible that amino acid mutations acquired
during serial passaging of PRRSV on MARC-145 cells
could result in attenuation as reported previously
(Allende et al., 2000; An et al., 2011). While this is also
applicable to the current study, we attempted to
minimize this risk, by using a relatively low passage of
both viruses with a pig passage followed by only two in
vitro passages in MARC-145 cells. Inoculation was
completed two days after weaning and transport of the
pigs to the research facility. It is also possible that the
stress from weaning, transport, new socialization, and
adjusting to a new environment may have affected the
ability of the pigs to respond to concurrent PRRSV-PCV2
infection and inﬂuenced the level of PRRSV replication in
the pigs. However, the data obtained from pigs infected
with PRRSV alone indicate that this was not the case and
that the ability of the pigs to develop a humoral immune
response was normal.
5. Conclusions
Overall, the data indicate no signiﬁcant differences
between the two PRRSV isolates based on clinical signs,
gross pathology, histology or hematology even though the
PRRSV isolates we utilized in this study were isolated from
geographically separated herds (VR-2385 from Iowa and
NC16845b from North Carolina) over a period of 15 years.
Differences in in vivo replication kinetics were identiﬁed.
VR-2385 initially replicated more quickly and to higher
levels and peaked at dpi 6 and the amount of VR-2385 RNA
steadily declined thereafter. In contrast, pigs infected with
NC16845b had lower levels of PRRSV RNA in serum
initially and this steadily increased through termination of
the study at dpi 12. Concurrent PCV2 viremia was
enhanced by PRRSV VR-2385 infection but not by
concurrent PRRSV NC16845b infection. A higher preva-
lence of PCV2 antigen was demonstrated in the lungs of
pigs coinfected with VR-2385 (83.3%) compared to pigs
coinfected with PRRSV NC16845b (66.7%). This work
further emphasizes in vivo replication differences among
PRRSV strains and the importance of coinfecting pathogens
on PRRSV kinetics. Additional investigations are necessary
to further elucidate the speciﬁc mechanisms of the PCV2-
PRRSV interaction in pigs.
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